Evaluation of Human Bocavirus (HBoV) as A Cause of Acute Gastroenteritis in Children Under 5 Years: A Case-Control Study
Abstract
Background: Acute gastroenteritis (AGE) is the main cause of infants and children's health problems, in developing countries, high morbidity and mortality rates were reported, Human Bocavirus (HBoV) are enteric viruses that linked to cause AGE.
Objective: To estimate the prevalence of HBoV infection in children under five years with AGE and to determine its genotypes by using conventional polymerase chain reaction and Sanger sequence.
Methods: This is a case-control study, the sample was collected from 100 children under 5 years of age suffering from AGE (as case group) and from 100 asymptomatic control children (as control group) from Central Teaching Hospital of Pediatrics from December 2021 to April 2022. Each children’s stool sample taken was stored at -20°C until they were employed in a conventional polymerase chain reaction to identify the HBoV genotypes.
Results: The rate of HBoV infection was found in 10% in AGE case group, while none of control group showed positive result. The genetic analysis showed that six of the investigated samples belonging to the HBoV-2 while four of the investigated samples belonging to the HBoV-3. In HBoV infected children, the age range (1-13 months) had most positive cases 5 (50%) and males had a greater infection rate (80%) than females (20%), however, non-significant association was found in regard to age and sex (P>0.05).
Conclusion: A low rate of HBoV DNA was detected in children under five years with AGE suggesting that other…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 100 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.